Nanoparticles for generating antigen-specific T cells for immunotherapy

Purpose: T cell therapies (TIL, TCR, CAR T) show clinical efficacy but are limited by high cost, lengthy ex vivo manufacturing, patient variability, and poor persistence. Nanoparticles offer a modular, universal platform to improve T cell therapy at every stage—from antigen presentation and T cell activation to T cell maintenance—while reducing cost and broadening patient accessibility.

Hypothesis: No formal experimental hypothesis. Central thesis: because nanoparticle properties (size, shape, elasticity, surface chemistry, ligand density) can be tuned for cell targeting, organ targeting, and cell internalization, nanoparticles can enhance or even replace endogenous cells at each step of generating and maintaining an antigen-specific T cell response.

Aims: Discuss unique applications of nanoparticles for antigen-specific T cell therapy. - Review nanoparticles as vaccines (to activate endogenous APCs). - Review nanoparticles as artificial antigen-presenting cells (aAPCs, to directly activate T cells). - Review nanoparticles as drug delivery vehicles (to support activated T cells). - Discuss nanoparticles for gene delivery to generate antigen-specific T cells (CAR/TCR engineering). - Discuss maintenance of antigen-specific responses via cytokine, small molecule, vaccine boost, and checkpoint blockade delivery.

Delivery system: Nanoparticle types: PLGA, PLGA/PBAE blends, PBAE nanoparticles, lipid nanoparticles (ionizable, cationic), liposomes, gold nanoparticles, iron oxide/magnetic nanoparticles (SPIO, magnetic nanoclusters), biomimetic magnetosomes, silica particles, mesoporous silica microrods, polystyrene particles, carbon nanotubes, hydrogel nanoparticles (PEG-based, 10–3000 kPa stiffness), nanogels, virus-like particles (VLPs), quantum dots, graphene oxide, calcium phosphate nanoparticles, fullerene derivatives. - Payloads/cargo: pMHC complexes, anti-CD3, anti-CD28, anti-CD137, anti-PD-1/PD-L1, IL-2, IL-12, IL-15SA, IL-21, TGF-β inhibitors, PI3K inhibitors, IDO inhibitors, imiquimod, α-GalCer, CpG-ODN, poly(I:C), MPL, R837, mRNA (CAR, TCR), plasmid DNA (CAR, IL-12, 4-1BBL), siRNA (PD-L1), antigens (OVA, TRP2, MART-1, gp100, CEA, WT1, HA). - Targeting strategies: mannose, fucose, glucan (CLR targeting); TLR ligands; CD11c; DEC-205; DC-SIGN; anti-CD8; anti-CD3ε F(ab′)2; CD47 "don't eat me" signal; iRGD tumor-targeting peptide; magnetic guidance; click chemistry (azide-functionalized leukocyte membranes). - Key design parameters: size (>1000 nm phagocytosis; 200–1000 nm macropinocytosis; ~250 nm clathrin/caveolae), shape (ellipsoidal > spherical for T cell activation and reduced macrophage uptake), stiffness/elasticity (softer particles circulate longer; softer substrates increase CD3 clustering), surface fluidity, ligand density and spacing, zeta potential.

Approach: Review of preclinical literature with no primary experiments. In vitro systems include primary human and mouse T cells, CD8⁺ T cells, CD4⁺ T cells, Tregs, dendritic cells, macrophages, B cells, PBMCs from melanoma patients, and tumor cell lines. In vivo models include B16 melanoma, B16-OVA melanoma, E.G7-OVA lymphoma, Nalm-6 leukemia, prostate cancer, hepatocellular carcinoma, and experimental autoimmune encephalomyelitis (EAE). Clinical context includes FDA-approved CAR T products, TIL and TCR therapy trials, and tumor cell vaccines already in the clinic.

Key methods: T cell expansion (fold expansion), proliferation, and phenotype (memory markers CD44⁺CD62L⁺, stem cell memory). - Antigen-specific T cell enrichment and expansion (E+E) via magnetic columns. - T cell activation: CD3 clustering, IFN-γ secretion, cytokine production (TNF-α, IL-2). - Cytotoxicity and target cell killing assays. - DC/APC maturation: CD40, CD80, CD86, MHC I/II expression. - Cross-presentation and pMHC tetramer staining. - In vivo tumor growth, tumor burden, survival, and lymph node accumulation. - Imaging: MRI, NIR fluorescence, SPECT. - Nanoparticle characterization: size, shape, stiffness, surface fluidity, ligand density, zeta potential.

Key results: Nano-aAPC E+E expanded Kb-TRP2 cognate cells from ~0.03% to 17.6% by day 7; nano-aAPCs expanded MART-1-specific CD8⁺ T cells more effectively than autologous DCs and CD3/CD28 Dynabeads, with higher stem cell memory populations. - PLGA aAPCs led to 30-fold (PMEL) and 20-fold (2C) expansion of transgenic CD8⁺ T cells; addition of PD-1 blockade increased IFN-γ secretion 3.5-fold. - PLGA/PBAE blend aAPCs achieved 1.5-fold increase in signal conjugation efficiency, bound more antigen-specific T cells (35-fold increase in mean fluorescence intensity), and produced 15-fold greater expansion versus PLGA-only aAPCs. - Azide-functionalized magnetic nanocluster aAPCs achieved 78-fold expansion by day 3. - Dendritic cell membrane-coated PLGA aAPCs increased CD8⁺ T cell population by 26% and increased TNF-α and IFN-γ by 8.7- and 8.4-fold. - Ellipsoidal aAPCs: 2-fold greater cognate CD8 T cell expansion in vivo and reduced tumor growth versus spherical particles; spherical aAPCs were more readily engulfed by macrophages. - Soft (10 kPa) versus hard (3000 kPa) PEG hydrogel NPs: soft NPs had longer distribution and elimination half-lives; hard NPs were phagocytosed at much higher rates. - Increased surface fluidity of silica particles significantly increased fold expansion of human T cells. - IVT mRNA-loaded PBAE/PGA NPs with anti-CD8 coating transfected T cells in vivo with CD19-specific 1928z CAR; eradicated 70% of tumors and improved survival by 37 days versus 60% and 32 days for virally transduced CAR T cells. - Anti-CD3ε F(ab′)2-decorated PBAE NPs delivering 194-1BBz CAR DNA led to 5.5-fold CAR T cell proliferation and increased memory-like phenotype (CD44⁺CD62L⁺). - Yeste et al.: myelin antigen-loaded nanoparticles induced 3-fold more FoxP3⁺ CD4⁺ T cells and fully suppressed EAE. - CARVac (lipid mRNA vaccine + CAR T): complete tumor rejection after inoculation versus delayed tumor onset with CAR T alone. - Jin et al.: magnetic nanoparticles increased DC accumulation in draining lymph nodes 11-fold, corresponding to almost complete tumor growth inhibition. - IL-15SA nanogel backpacks increased intratumoral T cell expansion and enabled CAR T cell-mediated tumor clearance. - Trident nanogel with PD-L1 peptide agonist + IDO inhibitor improved T cell survival in the TME.

Interpretation: Nanoparticles can generate antigen-specific T cell responses by targeting professional APCs (DCs, macrophages), non-professional APCs (B cells, cancer cells), or T cells directly via aAPCs. Nanoparticle aAPCs can dramatically enrich rare antigen-specific T cells (frequency ~1/100,000) and support maintenance through cytokine delivery, small molecules, vaccine boosts, and checkpoint blockade. The authors argue nanoparticles can reduce the cost and complexity of T cell therapy and enable "universal" or "off-the-shelf" antigen-agnostic approaches, broadening patient access.

Limitations: Review article; no primary data. - Most systems remain preclinical; clinical translation limited. - Lymph node delivery of vaccine components is inefficient; mechanistic understanding of cross-presentation is incomplete. - DCs are often dysfunctional in cancer patients and can be skewed immunosuppressive by the TME. - Antigen-specific B cells are rare (<0.05% of all B cells), hindering B cell-based APC approaches. - T cells are difficult to transfect non-virally due to limited endocytosis; electroporation has low transfection rates and decreases viability. - Viral vectors carry risks of insertional mutagenesis, prolonged CAR expression, cytokine release syndrome, and pre-existing immunity. - Nanoparticle parameters (size, shape, stiffness, surface chemistry) have complex, sometimes conflicting effects on uptake and immune response. - Immune cell subsets are heterogeneous and more research is needed to target subsets individually and reduce off-target effects. - Citation diversity statement notes limitations in name-based gender/race prediction methods.